
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934**

For the month of August 2022

Commission File Number: **001-38064**

Aeterna Zentaris Inc.

(Translation of registrant's name into English)

c/o Norton Rose Fulbright Canada, LLP, 222 Bay Street, Suite 3000, PO Box 53, Toronto ON M5K 1E7
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):



Exhibits 99.1 and 99.2, included with this report on Form 6-K are hereby incorporated by reference into the Registrant's Registration Statements on Forms S-8 (No. 333-224737, No. 333-210561 and No. 333-200834), Forms F-3 (No.333-232935 and No. 333-254680) and Forms F-1 (No.333-239264, No. 333-248561 and No. 333-239019) and shall be deemed to be a part thereof from the date on which this report is furnished, to the extent not superseded by documents or reports subsequently filed or furnished.

DOCUMENTS INDEX

Exhibit	Description
99.1	<u>Aeterna Zentaris' Condensed Interim Consolidated Financial Statements – Second Quarter 2022 (Q2)</u>
99.2	<u>Aeterna Zentaris' Management's Discussion and Analysis of Financial Condition and Results of Operations – Second Quarter 2022 (Q2)</u>
99.3	<u>Certification of the Chief Executive Officer pursuant to National Instrument 52-109</u>
99.4	<u>Certification of the Principal Financial Officer pursuant to National Instrument 52-109</u>

(2)



SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AETERNA ZENTARIS INC.

Date: August 3, 2022

By: */s/ Klaus Paulini*

Klaus Paulini
President and Chief Executive Officer

(3)



CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
AS AT JUNE 30, 2022 AND FOR THE THREE AND SIX MONTH PERIODS ENDED JUNE 30, 2022 AND 2021
(In thousands of US dollars)
(Unaudited)

Condensed Interim Consolidated Statements of Financial Position	2
Condensed Interim Consolidated Statements of Changes in Shareholders' Equity	3
Condensed Interim Consolidated Statements of Comprehensive Loss	4
Condensed Interim Consolidated Statements of Cash Flows	5
Notes to Condensed Interim Consolidated Financial Statements	6



CONDENSED INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
(In thousands of US dollars)
(Unaudited)

	<u>June 30, 2022</u>	<u>December 31, 2021</u>
	\$	\$
ASSETS		
Current assets		
Cash and cash equivalents	58,157	65,300
Trade and other receivables (note 4)	907	1,314
Inventory	261	73
Income taxes receivable	1,389	2,361
Prepaid expenses and other current assets (note 5)	2,459	1,772
Total current assets	63,173	70,820
Restricted cash equivalents	314	335
Right of use assets	114	150
Property, plant and equipment	42	42
Other non-current assets	122	—
Identifiable intangible assets	573	625
Goodwill	7,487	8,130
Total Assets	71,825	80,102
LIABILITIES		
Current liabilities		
Payables and accrued liabilities (note 6)	2,635	2,672
Current portion of provisions	27	34
Income taxes payable	105	115
Current portion of deferred revenues (note 3)	3,534	4,815
Current portion of lease liabilities	106	130
Total current liabilities	6,407	7,766
Deferred revenues (note 3)	2,617	1,493
Deferred gain	90	98
Lease liabilities	16	31
Employee future benefits (note 7)	8,188	17,485
Provisions	213	243
Total liabilities	17,531	27,116
SHAREHOLDERS' EQUITY		
Share capital (note 8)	293,410	293,410
Warrants (note 8)	5,085	5,085
Other capital (note 8)	89,848	89,788
Deficit	(333,450)	(334,619)
Accumulated other comprehensive loss ("AOCI")	(599)	(678)
Total shareholders' equity	54,294	52,986
Total liabilities and shareholders' equity	71,825	80,102

Commitments (note 12)
Subsequent events (note 13)

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

Approved by the Board of Directors

/s/ Carolyn Egbert

Carolyn Egbert
Chair of the Board

/s/ Dennis Turpin

Dennis Turpin
Director



**CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY
FOR THE SIX MONTHS ENDED JUNE 30, 2022 AND 2021**
(In thousands of US dollars, except share data, unaudited)

	<u>Common shares (number of)</u>	<u>Share capital \$</u>	<u>Warrants \$</u>	<u>Other capital \$</u>	<u>Deficit \$</u>	<u>Accumulated other comprehensive income (loss) \$</u>	<u>Total \$</u>
Balance - January 1, 2022	4,855,876	293,410	5,085	89,788	(334,619)	(678)	52,986
Net loss	—	—	—	—	(6,856)	—	(6,856)
Other comprehensive loss:							
Foreign currency translation adjustments	—	—	—	—	—	79	79
Actuarial gain on defined benefit plans and Remeasurement of the net defined benefit liability (note 7)	—	—	—	—	8,025	—	8,025
Comprehensive income	—	—	—	—	1,169	79	1,248
Share-based compensation costs	—	—	—	60	—	—	60
Balance – June 30, 2022	4,855,876	293,410	5,085	89,848	(333,450)	(599)	54,294
	<u>Common shares (number of)</u>	<u>Share capital \$</u>	<u>Warrants \$</u>	<u>Other capital \$</u>	<u>Deficit \$</u>	<u>Accumulated other comprehensive income (loss) \$</u>	<u>Total \$</u>
Balance - January 1, 2021	2,507,145	235,008	12,402	89,505	(322,659)	(1,045)	13,211
Net loss (as restated note 1)	—	—	—	—	(3,542)	—	(3,542)
Other comprehensive loss:							
Foreign currency translation adjustments	—	—	—	—	—	421	421
Actuarial gain on defined benefit plans	—	—	—	—	(86)	—	(86)
Comprehensive loss	—	—	—	—	(3,628)	421	(3,207)
Issuance of common shares, net of transaction costs	943,448	29,082	1,897	—	—	—	30,979
Exercise of warrants	1,400,447	29,769	(9,728)	—	—	—	20,041
Transfer of warrant issuance costs upon 2021 exercise of warrants (note 8)	—	(532)	532	—	—	—	—
Exercise of deferred share units (note 8)	840	20	—	(28)	—	—	(8)
Share-based compensation costs	—	—	—	273	—	—	273
Balance – June 30, 2021	4,851,880	293,347	5,103	89,750	(326,287)	(624)	61,289

The accompanying notes are an integral part of these condensed interim consolidated financial statements.



CONDENSED INTERIM CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2022 AND 2021
(In thousands of US dollars, except share and per share data)
(Unaudited)

	Three months ended June 30		Six months ended June 30	
	2022	2021 (As restated- Note 1)	2022	2021 (As restated- Note 1)
	\$	\$	\$	\$
Revenues (note 3)				
License fees	(206)	492	226	1,016
Development Services	(77)	1,030	889	2,125
Product sales	—	—	57	—
Royalties	24	19	43	27
Supply chain	37	43	80	84
Total revenues	(222)	1,584	1,295	3,252
Operating expenses				
Cost of sales	13	12	92	41
Research and development expenses	2,398	1,768	4,788	3,226
General and administrative expenses	1,781	1,645	3,339	2,909
Selling expenses	302	318	605	564
Total operating expenses	4,494	3,743	8,824	6,740
Loss from operations	(4,716)	(2,159)	(7,529)	(3,488)
Gain (loss) due to changes in foreign currency exchange rates	502	82	676	(166)
Other finance costs	(2)	(7)	(3)	(17)
Net finance income (costs)	500	75	673	(183)
Loss before income taxes	(4,216)	(2,084)	(6,856)	(3,671)
Income tax recovery	—	—	—	129
Net loss	(4,216)	(2,084)	(6,856)	(3,542)
Other comprehensive loss:				
Items that may be reclassified subsequently to profit or loss:				
Foreign currency translation adjustments	42	(126)	79	421
Items that will not be reclassified to profit or loss:				
Actuarial gain (loss) on defined benefit plans (note 7)	5,276	(968)	8,025	(86)
Comprehensive income (loss)	1,102	(3,178)	1,248	(3,207)
Net loss per share [basic and diluted]	(0.87)	(0.43)	(1.41)	(0.82)
Weighted average number of shares outstanding (note 11):				
Basic	4,855,876	4,848,129	4,855,876	4,335,821
Diluted	4,855,876	4,848,129	4,855,876	4,335,821

The accompanying notes are an integral part of these condensed interim consolidated financial statements.



CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2022 AND 2021
(In thousands of US dollars)
(Unaudited)

	Three months ended June 30,		Six months ended June 30,	
	2022	2021 (As restated- Note 1)	2022	2021 (As restated- Note 1)
	\$	\$	\$	\$
Cash flows from operating activities				
Net loss for the period	(4,216)	(2,084)	(6,856)	(3,542)
Items not affecting cash and cash equivalents:				
Provision	7	1	5	20
Depreciation and amortization	35	36	71	72
Share-based compensation costs	33	260	60	273
Employee future benefits (note 7)	98	50	197	99
Amortization of deferred revenues	124	(492)	(704)	(1,016)
Foreign exchange on items denominated in foreign currencies	(513)	(54)	(687)	212
Gain on disposal of property, plant and equipment	—	(1)	—	(1)
Other non-cash items	495	(114)	509	(85)
Interest accretion on lease liabilities	—	1	—	3
Payment (refund) of income taxes	(51)	(517)	830	(1,641)
Other asset	—	(82)	—	(82)
Changes in operating assets and liabilities (note 9)	(862)	(639)	264	1,008
Net cash used in operating activities	(4,850)	(3,635)	(6,311)	(4,680)
Cash flows from financing activities				
Issuance of common shares (note 8)	—	—	—	34,200
Transaction costs (note 8)	—	—	—	(3,221)
Proceeds from exercise of warrants (note 8)	—	55	—	20,041
Payments on lease liabilities	(34)	(31)	(68)	(63)
Net cash provided by (used in) financing activities	(34)	24	(68)	50,957
Cash flows from investing activities				
Proceeds from disposal of property, plant and equipment	—	1	—	1
Purchase of intangible assets	—	—	—	(490)
Purchase of property and equipment	(42)	(3)	(48)	(20)
Net cash “used in” provided by investing activities	(42)	(2)	(48)	(509)
Effect of exchange rate changes on cash and cash equivalents	(513)	110	(716)	(171)
Net change in cash and cash equivalents	(5,439)	(3,503)	(7,143)	45,597
Cash and cash equivalents – Beginning of period	63,596	73,371	65,300	24,271
Cash and cash equivalents – End of period	58,157	69,868	58,157	69,868

The accompanying notes are an integral part of these condensed interim consolidated financial statements.



**NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
AS AT JUNE 30, 2022 AND FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2022 AND 2021
(amounts in thousands of US dollars, except share and per share data and as otherwise noted)
(Unaudited)**

1. Business overview

Summary of business

Aeterna Zentaris (the “Company” or “Aeterna”) is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The Company’s lead product, Macrilen™ (macimorelin), is the first and only U.S. Food and Drug Administration (“FDA”) and European Medicines Agency-approved oral test indicated for the diagnosis of patients with adult growth hormone deficiency (“AGHD”). Macrilen™ is currently marketed in the US through a license agreement (the “Novo Amendment”) between the Company and Novo Nordisk Health Care AG (“Novo”) and in the United Kingdom and Europe through a license agreement with Consilient Healthcare Inc (“Consilient” or “CH”) under the trade name of Ghryvelin®. The Company is also dedicated to the development of therapeutic assets and has recently taken steps to establish a pre-clinical pipeline to potentially address unmet medical needs across a number of indications with a focus on rare or orphan indications and with the potential for pediatric use.

These unaudited condensed interim consolidated financial statements were approved by the Board of Directors (the “Board”) on August 3, 2022.

Basis of presentation

These unaudited condensed interim consolidated financial statements have been prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board (“IFRS”) applicable to the preparation of interim financial statements, including IAS 34, Interim Financial Reporting. These unaudited condensed interim consolidated financial statements should be read in conjunction with the Company’s annual consolidated financial statements as at and for the year ended December 31, 2021. The accounting policies in these condensed interim consolidated financial statements are consistent with those presented in the Company’s annual consolidated financial statements, with the exception of the Company’s policy with respect to the government assistance which is as follows:

Government assistance

Amounts received or receivable resulting from government assistance programs, including grants and refundable investment tax credits for research and development, are accounted for in accordance with *IAS 20 - Accounting for government grants* and disclosure of government assistance and are recognized where there is reasonable assurance that the amount of government assistance will be received, and all attached conditions will be complied with. When the amount relates to an expense item such as research and development costs, it is recognized as income on a systematic basis as a reduction to the costs that it is intended to compensate. When the grant relates to an asset, it reduces the carrying amount of the asset and is then recognized as income over the useful life of the depreciable asset by way of a reduced depreciation charge.



**NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
AS AT JUNE 30, 2022 AND FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2022 AND 2021
(amounts in thousands of US dollars, except share and per share data and as otherwise noted)
(Unaudited)**

COVID-19 & Russia and Ukraine conflict

The rise in COVID-19 variants has caused delays in site initiation and patient enrollment in our DETECT-trial and may be impacting sales activities for Macrilen™ in the US. Further, the continuation of the COVID-19 pandemic and the Russia/Ukraine conflict may also cause some patients to be unwilling to enroll in our trials or be unable to comply with clinical trial protocols if such events impede patient movement or interrupt healthcare services, both of which would delay our ability to conduct clinical trials or release clinical trial results on a timely basis and could delay our ability to obtain regulatory approval and commercialize our product candidates. For the period ended June 30, 2022, the Company assessed the impact of the uncertainties around the COVID-19 pandemic and the Russia/Ukraine conflict on its judgments, estimates, accounting policies and amounts recognized in these unaudited condensed interim consolidated financial statements and determined that no adjustments were required to the carrying value of assets and liabilities. Management determined that the recruitment for the DETECT-trial may now continue until later into 2023 compared to the end of the 2022 year as anticipated at the end of the previous fiscal year. As such, amounts related to deferred revenue have been reclassified from current to long-term to reflect the revised timeline. We are currently assessing with Novo the impact on timelines and study cost. Preliminary indications are that the delays associated with COVID-19 and the Russia/Ukraine conflict will result in additional costs to the program. As such, this resulted in reversal of revenue in both the license fees and development services for the quarter and in negative revenues of \$0.2 million and \$0.1 million for the three-months ended June 30, 2022..

The Company will continue to monitor the impact of the development of the COVID-19 pandemic and Russia/Ukraine conflict in further reporting periods. Actual results could differ from these estimates, and such differences may be material.

Restatement of comparative period figures

At the end of the prior fiscal year 2021, the Company restated its previously reported condensed consolidated interim financial statements for the three-month period ended March 31, 2021 and the three-month and six-month periods ended June 30, 2021 and three-month and nine-month periods ended September 30, 2021 with respect to the recognition of revenue for the Novo Amendment, signed in November 2020. During the fourth quarter of 2021, management reassessed the classification of the development activities associated with the DETECT-trial and concluded that subsequent to the Novo Amendment, the parties no longer shared joint control of these activities and, as such, these development activities no longer met the definition of a joint operation, as defined in *IFRS 11* -Joint Arrangements. Therefore, pursuant to the guidance in *IFRS 15* -Revenue from Contracts with Customers, the Company reclassified the charges to Novo, from research and development expenses to development services revenue, in the related periods. In addition, the license fees related to the pediatric indication were adjusted to reflect the revised pattern of recognition as the performance obligation for the development services has now been combined with the pediatric license. In addition, the accounting for prepaid expenses and other assets and deferred revenues related the DETECT-trial expenses incurred was restated.



NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
AS AT JUNE 30, 2022 AND FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2022 AND 2021
(amounts in thousands of US dollars, except share and per share data and as otherwise noted)
(Unaudited)

The condensed interim consolidated financial statements were not adjusted and refiled at the time of discovery of the error, rather the comparatives are being corrected now with the filing of the interim financials for the period ended June 30, 2022. The impacts of the June 30, 2021 restatements are as follows (amounts in thousands, except for basic and diluted loss per share):

	<u>Previously reported</u>	<u>Effect of restatement</u>	<u>Amended</u>
	\$	\$	\$
Consolidated interim statement of loss and comprehensive loss for the three-month period ended June 30, 2021			
License fees	537	(45)	492
Development service revenues	—	1,030	1,030
Research and development expenses	738	1,030	1,768
Net loss	(2,039)	(45)	(2,084)
Total comprehensive loss	(3,133)	(45)	(3,178)
Basic and diluted loss per share	(0.42)	(0.01)	(0.43)
Consolidated interim statement of loss and comprehensive loss for the six-month period ended June 30, 2021			
License fees	1,074	(58)	1,016
Development service revenues	—	2,125	2,125
Research and development expenses	1,101	2,125	3,226
Net loss	(3,484)	(58)	(3,542)
Total comprehensive loss	(3,149)	(58)	(3,207)
Basic and diluted loss per share	(0.72)	(0.01)	(0.82)
Consolidated interim statement of financial position as of June 30, 2021			
Prepaid expenses and other current assets	3,308	1,067	4,375
Current portion of deferred revenues	2,125	1,111	3,236
Deficit	(326,229)	(58)	(326,287)

2. Critical accounting estimates and judgements

The preparation of condensed interim consolidated financial statements in accordance with IFRS requires management to make judgments, estimates and assumptions that affect the reported amounts of the Company's assets, liabilities, revenues, expenses and related disclosures. Judgments, estimates and assumptions are based on historical experience, expectations, current trends and other factors that management believes to be relevant at the time at which the Company's condensed interim consolidated financial statements are prepared.

Management reviews, on a regular basis, the Company's accounting policies, assumptions, estimates and judgments in order to ensure that the condensed interim consolidated financial statements are presented fairly and in accordance with IFRS applicable to interim financial statements. Critical accounting estimates and assumptions, as well as critical judgments used in applying accounting policies in the preparation of the Company's condensed interim consolidated financial statements, were the same as those applied to the Company's annual consolidated financial statements as at and for the year ended December 31, 2021 and December 31, 2020 and for the years ended December 31, 2021, and 2020.



NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
AS AT JUNE 30, 2022 AND FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2022 AND 2021
 (amounts in thousands of US dollars, except share and per share data and as otherwise noted)
 (Unaudited)

3. License and supply arrangements

On November 16, 2020, the Company, through AEZS Germany, entered into Novo Amendment of its existing License Agreement with Novo related to the development and commercialization of macimorelin. The Company earns license fees, product sales, royalties and supply chain revenue, in addition to development service revenue from conducting the Study P02, from Novo.

In June 2020, the Company entered into an exclusive distribution and quality agreement with MegaPharm Ltd. (“MegaPharm”) for the commercialization in Israel and in the Palestinian Authority of macimorelin to be used in the diagnosis of patients with adult growth hormone deficiency and in clinical development for the diagnosis of pediatric growth hormone deficiency (the “MegaPharm Agreement”). As of June 30, 2022, there have been no products supplied under this agreement. On December 7, 2020, the Company entered into an exclusive licensing agreement with “CH” for the commercialization of macimorelin in the European Economic Area and the United Kingdom (the “CH License Agreement”). The Company earns licenses fees and product sale revenue from CH.

The Company and NK Meditech Limited (“NK”) entered into a licensing agreement, effective November 30, 2021 and pursuant to which the Company granted to NK the exclusive right to commercialize (including marketing, selling and offering to sell) macimorelin in the Republic of Korea (the “ROK”) and as applicable, in the Democratic People’s Republic of Korea (“DPRK”) to the extent NK is allowed to use the aforementioned licensed rights in the latter (“NK License Agreement”). As of June 30, 2022, there have been no products supplied under this agreement.

The following table provides a summary of deferred revenue balances:

	June 30, 2022		
	Current	Non-Current	Total
	\$	\$	\$
Novo Amendment	3,523	1,050	4,573
CH License Agreement	11	1,440	1,451
NK License Agreement	—	127	127
Total	3,534	2,617	6,151

	December 31, 2021		
	Current	Non-Current	Total
	\$	\$	\$
Novo Amendment	4,791	23	4,814
CH License Agreement	24	1,334	1,358
NK License Agreement	—	136	136
Total	4,815	1,493	6,308



NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
AS AT JUNE 30, 2022 AND FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2022 AND 2021
(amounts in thousands of US dollars, except share and per share data and as otherwise noted)
(Unaudited)

4. Trade and other receivables

	<u>June 30, 2022</u>	<u>December 31, 2021</u>
	\$	\$
Trade accounts receivable (net of expected credit losses of \$55 (December 31, 2021 – (\$55))	490	877
Value-added tax	182	372
Grant receivable	179	—
Other	56	65
	<u>907</u>	<u>1,314</u>

In March 2022, the Company was awarded a monetary subsidy with respect to two pre-clinical programs—namely, the Company’s development of an oral vaccine against infections with SARS-CoV-2 and the development of a product candidate for the treatment of neuromyelitis optica. The subsidy was awarded pursuant to the provisions of the German Act on Tax Incentives for Research and Development, which provides direct reimbursement of certain qualifying R&D expenditures to eligible entities. The CoV-2 grant is related to R&D expenditures incurred in 2021 and during the first half year of 2022. The Neuromyelitis Optica grant is related to expenditures incurred in 2021 and during the first half of 2022.

5. Prepaid expenses and other current assets

	<u>June 30, 2022</u>	<u>December 31, 2021</u>
	\$	\$
Prepaid insurance	1,259	421
Prepaid research and development	1,111	1,329
Other	89	22
	<u>2,459</u>	<u>1,772</u>

6. Payables and accrued liabilities

	<u>June 30, 2022</u>	<u>December 31, 2021</u>
	\$	\$
Trade accounts payable	938	934
Salaries, employment taxes and benefits	120	531
Accrued research and development costs	995	596
Other accrued liabilities	582	611
	<u>2,635</u>	<u>2,672</u>



NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
AS AT JUNE 30, 2022 AND FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2022 AND 2021
(amounts in thousands of US dollars, except share and per share data and as otherwise noted)
(Unaudited)

7. Employee future benefits

The change in the Company's accrued benefit obligations is summarized as follows:

	Six months ended June 30, 2022			Year ended December 31, 2021
	Pension benefit plans \$	Other benefit plans \$	Total \$	Total \$
Change in plan liabilities				
Balances – Beginning of the period	29,313	99	29,412	15,435
Current service cost	33	5	38	65
Interest cost	149	—	149	88
Employee Contributions	7	—	7	—
Actuarial gain arising from changes in financial assumptions	(9,802)	—	(9,802)	(1,130)
Past service cost associated with multi-employer plan	—	—	—	16,137
Actuarial loss arising from change in current assumptions on funding of future pension increases	—	—	—	556
Benefits paid	(344)	(1)	(345)	(511)
Impact of foreign exchange rate changes	(2,098)	(8)	(2,106)	(1,228)
Balances – End of the period	<u>17,258</u>	<u>95</u>	<u>17,353</u>	<u>29,412</u>
Change in plan assets				
Balances – Beginning of the period	11,927	—	11,927	—
Presentation of plan assets as of December 31, 2021	—	—	—	11,963
Remeasurement of plan assets	(1,777)	—	(1,777)	—
Employer contributions	32	—	32	—
Employee contributions	7	—	7	—
Benefits paid	(122)	—	(122)	—
Impact of foreign exchange rate changes	(902)	—	(902)	(36)
Balances – End of the period	<u>9,165</u>	<u>—</u>	<u>9,165</u>	<u>11,927</u>
Net liability of the unfunded plans	7,574	95	7,669	12,749
Net liability of the funded plans	519	—	519	4,736
Net amount recognized as Employee future benefits	<u>8,093</u>	<u>95</u>	<u>8,188</u>	<u>17,485</u>
Amounts recognized:				
In net loss	181	6	187	(153)
In other comprehensive loss	(9,221)	(8)	(9,229)	2,408

The calculation of the pension benefit obligation is sensitive to the discount rate assumption. Discount rates were 1.1% at December 31, 2021 and 3.25% at June 30, 2022 causing all of the gain noted above.



**NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
AS AT JUNE 30, 2022 AND FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2022 AND 2021
(amounts in thousands of US dollars, except share and per share data and as otherwise noted)
(Unaudited)**

8. Share capital, warrants and other capital

The Company has an unlimited number of authorized common shares (being voting and participating shares) with no par value, as well as an unlimited number of preferred, first and second ranking shares, issuable in series, with rights and privileges specific to each class, with no par value.

2021

On February 19, 2021, the Company completed an underwritten public offering of 820,390 common shares at \$36.25 per common share, resulting in aggregate gross proceeds of \$29,739, before deducting underwriting discounts, commissions and offering expenses of \$2,837 (the “February 2021 Financing”). The Company also granted the underwriter and placement agent (the “Underwriter”), a 30-day over-allotment option to purchase up to 123,058 additional common shares at a price of \$36.25 per common share (the “Underwriter Option”). Additionally, the Company issued warrants underlying 57,427 common shares to the Underwriter, with each warrant bearing an exercise price of \$45.3125 (the “February 2021 Placement Agent Warrants”). The February 2021 Placement Agent Warrants expire on February 17, 2026.

On February 22, 2021, the underwriter exercised the Underwriter Option in full and received 123,058 common shares in exchange for gross proceeds to the Company of \$4,461. Upon exercise of the Underwriter Option, the Underwriter also an additional 8,614 February 2021 Placement Agent Warrants.

Aggregate gross proceeds received in connection with the February 2021 Financing totaled \$34,200, less cash transaction costs of \$3,221 and non-cash transaction costs, which represent the issue-date fair value of the February 2021 Placement Agent Warrants, of \$1,897.

The table presented below shows the inputs and assumptions applied to the Black-Scholes option pricing model in order to determine the fair value of these Placement agent warrants:

	Number of equivalent shares	Market value per share price	Weighted average exercise price	Risk- free annual interest rate	Expected volatility	Expected life (years)	Expected dividend yield
		(\$)	(\$)	(i)	(ii)	(iii)	(iv)
February 2021 Placement agent warrants – public offering	57,427	37.00	45.31	0.58734%	119.18%	4.99	0.00%
February 2021 Placement agent warrants – Underwriter Option	8,614	37.00	45.31	0.58544%	119.57%	4.98	0.00%

- (i) Based on United States Treasury Government Bond interest rates with a term that is consistent with the expected life of the warrants.
- (ii) Based on the historical volatility of the Company’s stock price over the most recent period consistent with the expected life of the warrants.
- (iii) Based upon time to expiry from the issuance date.
- (iv) The Company has not paid dividends and it does not intend to pay dividends in the foreseeable future.



**NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
AS AT JUNE 30, 2022 AND FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2022 AND 2021
(amounts in thousands of US dollars, except share and per share data and as otherwise noted)
(Unaudited)**

During the six-month period ended June 30, 2021, warrants were exercised as follows::

	Warrants exercised (number of underlying common shares)	Exercise Price	Aggregate proceeds to the Company
September 2019 Investor warrants	80,000	\$ 41.25	\$ 3,300
February 2020 Investor warrants	69,565	30.00	2,087
July 2020 Investor warrants	841,822	11.25	9,471
July 2020 Placement Agent warrants	74,667	14.0625	1,050
August 2020 Investor warrants	303,595	11.75	3,567
August 2020 Placement Agent warrants	34,798	17.6015625	612
	<u>1,404,447</u>		<u>\$ 20,087</u>

Other capital

	Six months ended June 30, 2022		
	Stock options (Number)	Weighted average exercise price (\$)	DSUs (Number)
Balance – January 1, 2022	43,455	22.00	16,920
Granted	2,000	9.00	—
Expired	—	—	—
Exercised	—	—	—
Balance – June 30, 2022	<u>45,455</u>	<u>21.25</u>	<u>16,920</u>

	Year ended December 31, 2021		
	Stock options (Number)	Weighted average exercise price (\$)	DSUs (Number)
Balance – January 1, 2021	20,256	36.00	6,920
Granted	23,200	10.50	11,200
Expired	(1)	14,756.25	—
Exercised	—	—	(1,200)
Balance – December 31, 2021	<u>43,455</u>	<u>22.00</u>	<u>16,920</u>



NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
AS AT JUNE 30, 2022 AND FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2022 AND 2021
(amounts in thousands of US dollars, except share and per share data and as otherwise noted)
(Unaudited)

Fair value input assumptions for US dollar stock option grants

The table below shows the assumptions, or weighted average parameters, applied to the Black-Scholes option pricing model in order to determine share-based compensation costs over the life of the awards.

		Six Months Ended June 30, 2022	Year Ended December 31 2021
Expected dividend yield	(a)	0.00%	0.00%
Expected volatility	(b)	115.80%	115.80%
Risk-free annual interest rate	(c)	1.23%	1.23%
Expected life (years)	(d)	5.71	5.71
Weighted average share price		\$ 0.42	\$ 0.42
Weighted average exercise price		\$ 0.42	\$ 0.42
Weighted average grant date fair value		\$ 0.35	\$ 0.35

- (a) The Company has not paid dividends and it does not intend to pay dividends in the foreseeable future.
- (b) Based on the historical volatility of the Company's stock price over the most recent period consistent with the expected life of the stock options, as well as on future expectations.
- (c) Based on United States Treasury Government Bond interest rates with a term that is consistent with the expected life of the stock options.
- (d) Based upon historical data related to the exercise of stock options, on post-vesting employment terminations and on future expectations related to exercise behavior.

9. Supplemental disclosure of cash flow information

	Three months ended June 30,		Six months ended June 30,	
	2022	2021	2022	2021
	\$	\$	\$	\$
Changes in operating assets and liabilities:				
Trade and other receivables	(255)	(547)	220	103
Inventory	—	1	(206)	(39)
Prepaid expenses and other current assets	(1,471)	408	(759)	315
Payables and accrued liabilities	(40)	(430)	119	(315)
Taxes payable	—	—	—	(129)
Deferred revenues	1,001	3	1,008	1,230
Employee future benefits	(97)	(74)	(118)	(157)
	(862)	(639)	264	1,008



NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
AS AT JUNE 30, 2022 AND FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2022 AND 2021
(amounts in thousands of US dollars, except share and per share data and as otherwise noted)
(Unaudited)

10. Segment information

The Company operates in a single operating segment, being the biopharmaceutical segment.

11. Net loss per share

The following table sets forth pertinent data relating to the computation of basic and diluted net loss per share attributable to common shareholders.

	Three months ended		Six months ended	
	June 30,		June 30,	
	2022	2021	2022	2021
	\$	\$	\$	\$
Net loss	(4,216)	(2,084)	(6,856)	(3,542)
Basic weighted average number of shares outstanding	4,855,876	4,848,129	4,855,876	4,335,821
Net loss income per share (basic)	(0.87)	(0.43)	(1.41)	(0.82)
Dilutive effect of stock options and DSUs	—	—	—	—
Dilutive effect of warrants	—	—	—	—
Diluted weighted average number of shares outstanding	4,855,876	4,848,129	4,855,876	4,335,821
Net loss per share (diluted)	(0.87)	(0.43)	(1.41)	(0.82)
Items excluded from the calculation of diluted net loss per share because the exercise price was greater than the average market price of the common shares or due to their anti-dilutive effect				
Stock options and DSUs	62,375	37,176	62,375	37,176
Warrants	457,649	461,649	457,649	461,649

Net loss per share is calculated by dividing net loss by the weighted average number of shares outstanding during the relevant period. Diluted weighted average number of shares reflects the dilutive effect of equity instruments, such as any “in the money” stock options, DSUs and warrants. In periods with reported net losses, all stock options and warrants are deemed anti-dilutive such that basic net loss per share and diluted net loss per share are equal, and thus “in the money” stock options and warrants have not been included in the computation of net loss per share because to do so would be anti-dilutive.

12. Commitments

	Service and	R&D	TOTAL
	manufacturing	contracts	
	\$	\$	\$
Less than 1 year	5,015	2,090	7,105
1 - 3 years	938	776	1,714
4 - 5 years	47	—	47
More than 5 years	—	—	—
Total	6,000	2,866	8,866

The Company executed various agreements including in-licensing and similar arrangements with development partners. Such agreements may require the Company to make payments on achievement of stages of development, launch or revenue milestones, although the Company generally has the right to terminate these agreements at no penalty.



NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
AS AT JUNE 30, 2022 AND FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2022 AND 2021
(amounts in thousands of US dollars, except share and per share data and as otherwise noted)
(Unaudited)

Based on the closing exchange rates at June 30, 2022, the Company expects to pay \$9,050 including \$6,804 (€6.5 million), and \$1,396 (£1.2 million) and \$850 USD, in R&D milestone payments and up to \$39,302, including \$28,785 (€27.6 million); \$1,517 (£1.3 million) and \$9,000 USD, in revenue related milestone payments. The table below contains all potential R&D and revenue-related milestone payments that the Company may be required to make under such agreements:

	Future potential R&D milestone payments	Future potential revenue milestone payments	TOTAL
	\$	\$	\$
Less than 1 year	26	—	26
1 - 3 years	204	—	204
4 - 5 years	1,990	—	1,990
More than 5 years	6,830	39,302	46,132
Total	9,050	39,302	48,352

The future payments that are disclosed represent contract payments and are not discounted and are not risk-adjusted. The development of any pharmaceutical product candidates is a complex and risky process that may fail at any stage in the development process due to a number of factors. The timing of the payments is based on the Company's current best estimate of achievement of the relevant milestone.

13. Subsequent Events

Reverse Stock Split

On July 15, 2022, the Company's shareholders and board of directors approved an amendment to the Company's articles of amendment to effect a 1-for-25 reverse stock split of the Company's common shares, DSU and Warrants. The Company's outstanding stock options were also adjusted to reflect the 1-for-25 reverse stock split of the Company's common shares. Accordingly, all common shares, DSU and Warrants, stock options and per share amounts in these consolidated financial statements have been retroactively adjusted for all periods presented to give effect to the reverse stock split. Outstanding stock options were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased. The reverse stock split was effected in the markets on July 21, 2022.



Management's Discussion and Analysis of Financial Condition and Results of Operations

Introduction

This Management's Discussion and Analysis ("MD&A") provides a review of the results of operations, financial condition and cash flows of Aeterna Zentaris Inc. for the three and six-months ended June 30, 2022. In this MD&A, "Aeterna Zentaris", "Aeterna" the "Company", "we", "us" and "our" mean Aeterna Zentaris Inc. and its subsidiaries. This discussion should be read in conjunction with the information contained in the Company's unaudited condensed consolidated financial statements and the accompanying notes thereto as at June 30, 2022 and for the three and six-months ended June 30, 2022 and 2021 and our audited consolidated financial statements and MD&A as of and for the year ended December 31, 2021. The unaudited condensed interim consolidated financial statements as at June 30, 2022 and for the three and six-months ended June 30, 2022 and 2021 were prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board ("IFRS") applicable to the preparation of interim financial statements, including IAS 34 and internal financial reporting. The Company's common shares are listed on both The Nasdaq Capital Market ("Nasdaq") and on the Toronto Stock Exchange ("TSX") under the symbol "AEZS".

All amounts in this MD&A are presented in United States ("U.S.") dollars, except as otherwise noted.

This MD&A was approved by the Company's Board of Directors on August 3, 2022. This MD&A is dated August 3, 2022.

Company Overview

Aeterna Zentaris is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The Company's lead product, Macrilen™ (macimorelin), is the first and only U.S. Food and Drug Administration and European Medicines Agency ("EMA") approved oral test indicated for the diagnosis of patients with adult growth hormone deficiency ("AGHD"). Macimorelin is currently marketed in the U.S. under the trade name Macrilen™ through the license agreement and the amended license agreement (collectively the "Novo Amendment") with Novo Nordisk Healthcare AG ("Novo Nordisk" or "Novo"), who was granted an exclusive license for the development, manufacturing, registration and commercialization of Macrilen™ (macimorelin) for the diagnosis of adult and pediatric growth hormone deficiency in the U.S. and Canada.

According to a commercialization and supply agreement, MegaPharm Ltd. is seeking regulatory approval and plans to subsequently commercialize macimorelin in Israel and the Palestinian Authority. Additionally, upon receipt of pricing and reimbursement approvals, Aeterna Zentaris has marketed macimorelin in Europe and the United Kingdom through license and supply agreements with Consilient Health Ltd. ("Consilient Health" or "CH") under which Aeterna Zentaris is entitled to receive: regulatory milestone payments related to agreed-upon pricing and reimbursement parameters; net sales milestone payments; and royalties, ranging from 10%-20% of net sales, subject to reduction in certain cases, or sublicense income recorded by Consilient Health. Commercialization in European countries started at the end of May 2022. The Company is also leveraging the clinical success and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency ("CGHD"), an area of significant unmet need. The Company is actively pursuing business development opportunities for the commercialization of macimorelin in Asia and the rest of the world. We entered into license and supply agreements with NK Meditech Ltd. ("NK"), a subsidiary of PharmBio Korea, effective November 30, 2021, and a distribution and commercialization agreement with ER Kim Pharmaceuticals Bulgaria Food ("ER-Kim"), effective February 1, 2022. The agreements with NK are related to the development and commercialization of macimorelin for the diagnosis of AGHD and CGHD in the Republic of Korea, while the agreement with ER-Kim is related to the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults in Turkey and some non-European Union Balkan countries.



The Company is also dedicated to the development of therapeutic assets and has taken steps to establish a pre-clinical pipeline to potentially address unmet medical needs across a number of indications with a focus on rare or orphan indications. To date, we have signed agreements to establish this growing pipeline across a number of indications, including neuromyelitis optica spectrum disorder (“NMOSD”), Parkinson’s disease, primary hypoparathyroidism and amyotrophic lateral sclerosis (“ALS”, also known as Lou Gehrig’s disease). Additionally, the Company is developing oral prophylactic bacterial vaccines against each of SARS-CoV-2, the virus that causes COVID-19, and chlamydia trachomatis.

About Forward-Looking Statements

This document contains statements that may constitute forward-looking statements within the meaning of U.S. and Canadian securities legislation and regulations, and such statements are made pursuant to the safe-harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. In some cases, these forward-looking statements can be identified by words or phrases such as “forecast”, “may”, “will”, “expect”, “anticipate”, “estimate”, “intend”, “plan”, “indicate”, “believe”, “direct”, or “likely”, or the negative of these terms, or other similar expressions intended to identify forward-looking statements. In addition, any statements that refer to expectations, intentions, projections and other characterizations of future events or circumstances contain forward-looking information.

Forward-looking statements are based on the opinions and estimates of the Company as of the date of this MD&A, and they are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking statements, including but not limited to the factors described under “Risk Factors” in our most recent Annual Report on Form 20-F and those relating to: Aeterna’s expectations with respect to the DETECT-trial (as further defined below) (including regarding the enrollment of subjects in the DETECT-trial, the application of the Macimorelin growth hormone stimulation tests and the completion of the DETECT-trial); Aeterna’s expectations regarding conducting pre-clinical research to identify and characterize an AIM Biologicals-based development candidate for the treatment of NMOSD as well as Parkinson’s disease (as further defined below), and developing a manufacturing process for selected candidates; Aeterna’s expectations regarding conducting assessments in relevant Parkinson’s disease models; The University of Queensland’s undertaking a subsequent investigator initiated clinical trial evaluating macimorelin as a potential therapeutic for the treatment of ALS and Aeterna’s formulating a pre-clinical development plan for same; the commencement of Aeterna’s formal pre-clinical development of AEZS-150 in preparation for a potential investigational new drug (“IND”) filing for conducting the first in-human clinical study of AEZS-150; Aeterna’s plans to perform challenge experiments, select a development candidate, start clinical development and establish a manufacturing process for the orally active COVID-19 (SARS-CoV-2) and Chlamydia live-attenuated bacterial vaccine.



Forward-looking statements involve known and unknown risks and uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Such risks and uncertainties include, among others: our reliance on the success of the pediatric clinical trial in the European Union and U.S. for Macrilen™ (macimorelin); the commencement of the DETECT-trial may be delayed or we may not obtain regulatory approval to initiate that study; we may be unable to enroll the expected number of subjects in the DETECT-trial and the result of the DETECT-trial may not support receipt of regulatory approval in CGHD; the coronavirus vaccine platform technology (and any vaccine candidates using that technology) licensed from the University of Wuerzburg has never been tested in humans, and as such, further pre-clinical or clinical studies of that technology and any vaccine developed using that technology may not be effective as a vaccine against COVID-19 (SARS-CoV-2) or against any other coronavirus disease; the timeline to develop a vaccine may be longer than expected; such technology or vaccines may not be capable of being used orally or may not have the same characteristics as vaccines previously approved using the Salmonella Typhi Ty21a carrier strain; results from ongoing or planned pre-clinical studies of macimorelin by the University of Queensland or for our other products under development may not be successful or may not support advancing the product to human clinical trials; our ability to raise capital and obtain financing to continue our currently planned operations; our dependence on the success of Macrilen™ (macimorelin) and related out-licensing arrangements and the continued availability of funds and resources to successfully commercialize the product, including our reliance on the success of the Novo Amendment; global instability due to the global pandemic of COVID-19 and COVID-19's impact on our operations, which, as discussed below, has resulted in and is expected to result in delays and higher-than-expected costs associated with our clinical development initiatives related to Macrilen™ in the pediatric indication; interruptions due to the Russian invasion of Ukraine, which has also resulted and is expected to result in delays and higher-than-expected costs associated with our clinical development initiatives related to Macrilen™ in the pediatric indication, as discussed below; our ability to enter into out-licensing, development, manufacturing, marketing and distribution agreements with other pharmaceutical companies and to keep such agreements in effect; and our ability to continue to list our common shares on the Nasdaq or the TSX. These risk factors are not intended to represent a complete list of the risk factors that could affect the Company. These factors and assumptions, however, should be considered carefully. More detailed information about these and other factors is included under "Risk Factors" in our most recent Annual Report on Form 20-F. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. Many of these factors are beyond our control. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements, particularly in light of the ongoing and developing COVID-19 pandemic and its impact on the global economy and its uncertain impact on the Company's business. Accordingly, readers should not place undue reliance on forward-looking statements. The Company does not undertake to update any forward-looking statements contained herein, except as required by applicable securities laws. New factors emerge from time to time, and it is not possible for the Company to predict all of these factors, or to assess in advance the impact of each such factor on the Company's business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statement.

Certain forward-looking statements contained herein about prospective results of operations, financial position or cash flows may constitute a financial outlook. Such statements are based on assumptions about future events, are given as of the date hereof and are based on economic conditions, proposed courses of action and management's assessment of the relevant information currently available. Management of the Company has approved the financial outlook as of the date hereof. Readers are cautioned that such financial outlook information contained herein should not be used for purposes other than for which it is disclosed herein.

About Material Information

This MD&A includes information that we believe to be material to investors after considering all circumstances. We consider information and disclosures to be material if they result in, or would reasonably be expected to result in, a significant change in the market price or value of our securities, or where it is likely that a reasonable investor would consider the information and disclosures to be important in making an investment decision.

We are a reporting issuer under the securities legislation of all of the provinces of Canada, and our securities are registered with the SEC. We are therefore required to file or furnish continuous disclosure information, such as interim and annual financial statements, management's discussion and analysis, proxy or information circulars, Form 20-F, material change reports and press releases with the appropriate securities regulatory authorities. Additional information about the Company and copies of these documents may be obtained free of charge upon request from our Corporate Secretary or online at: www.zentaris.com, www.sedar.com and www.sec.gov.



Diagnostic Commercial and Development Pipeline

Diagnostic Commercial and Development Pipeline



Macimorelin Clinical Program

On January 28, 2020, we announced the successful completion of patient recruitment for the first pediatric study of macimorelin as a growth hormone stimulation test for the evaluation of growth hormone deficiency (“GHD”) in children. This study, AEZS-130-P01 (“Study P01”), was the first of two studies as agreed with the EMA in our pediatric investigation plan for macimorelin as a GHD diagnostic. Macimorelin, a ghrelin agonist, is an orally active small molecule that stimulates the secretion of growth hormone from the pituitary gland into the circulatory system. The goal of Study P01 was to establish a dose that can both be safely administered to pediatric patients and cause a clear rise in growth hormone concentration in subjects ultimately diagnosed as not having GHD. The recommended dose derived from Study P01 is being evaluated in the pivotal second study, DETECT-trial, on diagnostic efficacy and safety.

In late 2020, Aeterna entered into the start-up phase for the clinical safety and efficacy study, AEZS-130-P02 (“DETECT-trial”), evaluating macimorelin for the diagnosis of CGHD. The DETECT-trial is an open-label, single dose, multicenter and multinational study expected to enroll approximately 100 subjects worldwide, with at least 40 pre-pubertal and 40 pubertal subjects, and a minimum of 25 subjects expected to be enrolled in the U.S. The study design is expected to be suitable to support a claim for potential stand-alone testing, if successful. In addition, under the Novo Amendment, Novo and Aeterna agreed that Novo will fund DETECT-trial costs up to \$11 million (€9 million), which includes reimbursement of Aeterna’s relevant budgeted internal labor costs. Any additional external jointly approved DETECT-trial costs incurred over \$11 million (€9 million) will be shared equally between Novo and Aeterna. On April 22, 2021, the U.S. FDA Investigational New Drug Application associated with this clinical trial became active, see: <https://clinicaltrials.gov/ct2/show/NCT04786873>, and on May 13, 2021, we announced the opening of the first clinical site in the U.S.

On January 26, 2022, the Company announced that it had experienced unavoidable delays in site initiation and patient enrollment due to the rise of the Omicron variant in the COVID-19 pandemic. Our team is diligently working to get more clinical sites up and running with the goal of building momentum and bringing this study across the finish line while navigating as best as possible through this challenge. We have engaged a contract research organization (“CRO”) to conduct the DETECT-trial in the United States and in various European countries, including Russia and Ukraine, where, in February 2022, due to the war between those nations, the clinical trial activities were halted. Consequently, no patients have been enrolled in either of these countries’ clinical sites to date. Russia’s invasion of Ukraine has impacted our ability to conduct our trials in the region. This could delay or hinder the completion of our clinical trials and/or analyses of clinical results, which could materially harm our business.

Management’s current estimated impacts of delays and higher-than-expected costs related to Macrilen’s™ pediatric clinical development due to both COVID-19 and the Russia/Ukraine war are discussed further below.



Macimorelin Pre-clinical Program

On January 13, 2021, we entered into a material transfer agreement with Queensland University to provide macimorelin for the conduct of preclinical and clinical studies evaluating macimorelin as a therapeutic for the treatment of amyotrophic lateral sclerosis (“ALS”, or more commonly known as Lou Gehrig’s disease). Queensland University researchers have filed funding applications to dedicated organizations in Australia to finance parts of the abbreviated preclinical development program and to conduct a subsequent investigator-initiated clinical trial to evaluate the safety, tolerability and efficacy of macimorelin as a potential new treatment option for ALS patients. The Company expects to continue work with Queensland University but also to conduct independent proof-of-concept studies with macimorelin in diseasespecific ALS animal models, assess alternative formulations and formalize a preclinical development plan.

The Company is developing additional alternative formulations for administration routes more suitable for ALS with the goal of ensuring sufficient bioavailability and expects to provide updates on its progress as results become available.

Macimorelin Commercialization Program

On November 16, 2020, the Company announced that it had entered into the Novo Amendment related to the development and commercialization of macimorelin. Novo is currently marketing macimorelin in the U.S. under the trade name Macrilen™ for the diagnosis of AGHD. Aeterna, in collaboration with Novo, is currently developing the expanded use of macimorelin for the diagnosis of CGHD, an area of significant unmet medical need.


On December 7, 2020, the Company entered into an exclusive licensing agreement with Consilient Health Limited (“CH” or “Consilient”) for the commercialization of macimorelin in the European Economic Area and the United Kingdom. In December 2021, the Department of Health and Social Care in the United Kingdom approved a list price which triggered a \$226 (€0.2 million) pricing milestone payment from CH to the Company. In Germany, a list price was approved on June 15, 2022 which triggered a second \$226 (€0.2 million) pricing milestone payment from CH to the Company. We shipped initial batches of macimorelin (Ghryvelin®) to Consilient in the first quarter of 2022. Consilient launched the product in the United Kingdom, Sweden and Denmark in May 2022 and launches in Germany and Finland are scheduled for July 2022.

We entered into license and supply agreements with NK Meditech Ltd. (“NK”), a subsidiary of PharmBio Korea, effective November 30, 2021, and a distribution and commercialization agreement with ER Kim Pharmaceuticals Bulgaria Food (“ER-Kim”), effective February 1, 2022. The agreements with NK are related to the development and commercialization of macimorelin for the diagnosis of AGHD and CGHD in the Republic of Korea, while the agreement with ER-Kim is related to the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults in Turkey and some non-European Union Balkan countries.

On April 19, 2022, we announced that European Patent Office had issued a patent providing intellectual property protection of macimorelin in 27 countries within the European Union as well as additional European non-EU countries, such as the UK and Turkey, for macimorelin (Ghryvelin®; Macrilen™) for use to diagnose GHD in adults.



Pipeline Expansion Opportunities



Bacterial Vaccine Platform: Orally active, live-attenuated bacterial vaccine platform with potential application against viruses and bacteria, such as coronaviruses and chlamydia bacteria

On February 2, 2021, the Company announced that it had entered into an exclusive option agreement (the “University License Agreement”) to evaluate a preclinical potential COVID-19 vaccine developed at the University of Wuerzburg (the “University”). On March 14, 2021, the Company exercised the option to enter into a license agreement with the University. Pursuant to the terms of the University License Agreement, the Company has been granted an exclusive, world-wide, license to certain patent applications and know-how owned by the University to research and develop, manufacture, and sell a potential COVID-19 vaccine using the University’s bacterial vaccine platform technology. The Company has paid an up-front payment under the University License Agreement and will conduct milestones payments upon achievement of certain development, regulatory, and sales milestones, as well as a percentage of any sub-licensing revenue received by the Company as well as royalty payments on net sales of the licensed vaccine products (including for by the Company or its sub-licensees). Pursuant to the University License Agreement, the University granted the Company an exclusive option for the exclusive use of the licensed rights in an undisclosed field. In September 2021, the Company exercised this option and disclosed the field to be Chlamydia trachomatis. Additionally, the Company has entered into a research agreement under which the Company has engaged the University on a fee-for-service basis to conduct supplementary research activities and preclinical development studies on the potential vaccines.

The vaccine technology developed at the University is based on the active live-attenuated bacterial typhoid fever vaccine Salmonella Typhi Ty21a with an excellent safety profile, as a carrier strain. Our vaccines have the potential to be administered orally (topically), induce mucosal immunity, believed to be critical to suppress infection, induce a response to more than one antigen (similar to the spike protein), and be stored and distributed at 2°C to 8°C. We believe that, if there is sufficient data to advance into human clinical trials, the development program for these vaccines is expected to be abbreviated, as clinical safety data and manufacturing technology is already available for the underlying vaccine strain.

The Coronavirus outbreak began in the end of 2019 and in early 2022 was reaching its fourth infection peak worldwide with vaccinated people getting infected and with booster vaccinations being needed. The competition is large with 11 vaccines currently being in clinical studies only in Europe. Our COVID-19 vaccine candidate is unique in stimulating the mucosal immune system giving the potential to eliminate the virus when it enters the body, before an infection can occur, and drastically reducing the risk of vaccinated people getting infected and spreading the virus. In addition, the oral application and its expected storage stability should greatly facilitate distribution and administration. Our next development steps include evaluating the administration route, dose and immunization scheme; initiating in-vivo immunology experiments with antigen variant candidates in relevant mice models; conducting virus challenge experiments in immunized transgenic animals; starting the manufacturing process assessment / development; and conducting pre-clinical safety and toxicology assessments.



Chlamydia trachomatis is a sexually transmitted bacterium infecting over 130 million subjects annually. In US, the prevalence 2.4 million per year, the incidence is 4 million per year, and the associated yearly health cost \$691 million. The disease can spread to the reproductive tract eventually inducing infertility, miscarriage, or ectopic pregnancy, which is a life-threatening condition. Additionally, ocular infections can lead to inclusion conjunctivitis or trachoma, which is the primary source of visual impairment or infectious blindness. While diagnosed infections can be treated with antibiotics, three quarters of all infections are asymptomatic and currently no vaccine exists to protect against chlamydia. The potential strengths of our chlamydia vaccine candidate are the mucosal immunity, oral administration, good stability, and inexpensive production. Our next development steps include designing and preparing candidate vaccine strains; evaluating administration route, dose and immunization scheme; and initiating in-vivo immunology experiments with candidate strains in relevant mouse models.

On March 10, 2022, the Company announced the expansion of its research program with the University of Wuerzburg to include the development of human 3D intestinal tissue models to study infection biology in the gut, the site of Salmonella primary action.

Delayed Clearance Parathyroid Hormone (“DC-PTH”) Fusion Polypeptides: Potential treatment for chronic hypoparathyroidism

On March 11, 2021, the Company entered into an exclusive license agreement with The University of Sheffield, United Kingdom, for the intellectual property relating to parathyroid hormone (“PTH”) fusion polypeptides covering the field of human use, which is being initially studied by Aeterna for the potential therapeutic treatment of chronic hypoparathyroidism (“HypoPT”). Under the terms of the exclusive patent and know-how license agreement entered into with the University of Sheffield, Aeterna obtained worldwide rights to develop, manufacture and commercialize PTH fusion polypeptides covered by the licensed patent applications for all human uses for an up-front cash payment, and milestone payments to be paid upon the achievement of certain development, regulatory and sales milestones, as well as low single digit royalty payments on net sales of those products and certain fees payable in connection with sublicensing. Aeterna will be responsible for the further development, manufacturing, approval, and commercialization of the licensed products. Aeterna has also engaged the University of Sheffield under a research contract to conduct certain research activities to be funded by Aeterna, the results of which will be included within the scope of the license granted to Aeterna.

The researchers at the University of Sheffield have developed a method to increase the serum clearance time of peptides, which the Company is applying to the development of a treatment for HypoPT, an orphan disease where the PTH level is abnormally low or absent. In consultation with The University of Sheffield, Aeterna has selected AEZS-150 as the lead candidate in its DC-PTH program. AEZS-150 is being developed to provide a weekly treatment option of chronic hypoparathyroidism in adults and our next steps include working with The University of Sheffield to conduct indepth characterization of the development candidate (in-vitro and in-vivo). We have selected and engaged a contract development and manufacturing company for developing the manufacturing process; and are preparing for the formal pre-clinical development of AEZS-150 in preparation for a potential IND filing for conducting the first in-human clinical study.

AIM Biologicals: Targeted, highly specific autoimmunity modifying therapeutics for the potential treatment of neuromyelitis optica spectrum disorder and Parkinson’s disease

In January 2021, Aeterna entered into an exclusive patent license and research agreement with the University of Wuerzburg, Germany, for worldwide rights to develop, manufacture, and commercialize AIM Biologicals for the potential treatment of NMOSD. Additionally, the Company has engaged Dr. Joerg Wischhusen from the University Hospital in Wuerzburg as well as neuro-immunologist Dr. Michael Levy from the Massachusetts General Hospital in Boston as consultants for scientific support and advice in the field of inflammatory CNS disorders, autoimmune diseases of the nervous system, and NMOSD. In September 2021, the Company entered into an additional exclusive license with the University of Wuerzburg for early pre-clinical development towards the potential treatment of Parkinson’s disease.

AIM Biologicals is based on a feto-maternal-tolerance, natural process during pregnancy, which induces immunogenic tolerance of the maternal immune system to the partially foreign fetal antigens. Fetal proteins are processed and presented on certain immunosuppressive major histocompatibility complex class I molecules to induce this tolerance. In an autoimmune disease, the immune system is misdirected and targets the body’s own protein. With AIM Biologicals, we aim to restore the tolerance against such proteins to selectively treat autoimmune diseases.

NMOSD is an autoimmune disease targeting the protein aquaporin 4, primarily found in optic nerves and the spinal cord, and is a disease which leads to blindness and paralysis, more commonly in persons with Asian or African ancestors as compared to European ancestors, and more prevalent among women. NMOSD progresses in often life-threatening relapses, which are aggressively treated with high-dose steroids and plasmapheresis. Our pre-clinical plans include conducting in-vitro and in-vivo assessments to select an AIM Biologicals-based development candidate; and manufacturing process development for the selected candidate.



Parkinson's disease is a neurological disease commonly associated with motoric problems with a slow and fast progression form. Dopaminergic medication is the mainstay treatment of Parkinson disease symptoms, but currently there is no pharmacological therapy to prevent or delay disease progression leading to alternate treatments, such as deep brain stimulation with short electric bursts, being investigated for the treatment of symptoms. For the development of AIM Biologicals as potential PD therapeutics, Aeterna plans to utilize, among others, an innovative animal model on neurodegeneration by α -synuclein-specific T cells in AAV-A53T- α -synuclein Parkinson's disease mice, which has recently been published by University of Wuerzburg researchers. Our next steps include designing and producing antigen-specific AIM Biologics molecules for the potential treatment of Parkinson's disease; and conducting in-vitro and in-vivo assessments in relevant Parkinson's disease models.

Macimorelin Therapeutic: Ghrelin agonist in development for the treatment of amyotrophic lateral sclerosis (Lou Gehrig's disease)

In January 2021, the Company entered into a material transfer agreement with the University of Queensland, Australia, to provide macimorelin for the conduct of pre-clinical and subsequent clinical studies, evaluating macimorelin as a potential therapeutic for the treatment of ALS. ALS is a rare progressive neurological disease primarily affecting the neurons controlling voluntary movement, leading to the disability to control movements such as walking, talking, and chewing. Most people with ALS die from respiratory failure, usually between three to five years after diagnosis. Currently there is no cure for ALS and no effective treatment to halt or reverse the progression of the disease. Ghrelin is a hormone with wide-ranging biological actions, best known for stimulating growth hormone release, which is demonstrating emerging evidence as therapeutic for ALS. As a ghrelin agonist, macimorelin has the potential as a treatment for ALS, which is evaluated in this research collaboration. The University of Queensland researchers have filed for supportive grants to conduct such clinical studies. AEZS and the UniQuest, the University of Queensland commercialization company, have signed a R&D and license option agreement effective July 1st, 2022. Our next steps include working with the University of Queensland to conduct proof-of-concept studies with macimorelin in disease-specific animal models, assessing alternative formulations and formalizing a pre-clinical development plan.

Changes in personnel and advisors

Effective January 24, 2022, Mr. Giuliano La Fratta joined the Company as the Senior Vice President, Chief Financial Officer, replacing Ms. Leslie Auld.

Nasdaq Letters and Share Consolidation

On July 28, 2021, we received a letter from the Listing Qualifications Staff of the Nasdaq, notifying us that during the 30 consecutive business days prior to the date of the letter, the closing bid price of our common shares was below US\$1.00 per share and, therefore, we did not meet the requirement for continued listing on Nasdaq as required by Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Rule"). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we were granted a grace period of 180 calendar days, through January 24, 2022. On January 26, 2022, we announced that the Listing Qualifications Staff of the Nasdaq had notified the Company that it has been granted an additional 180 calendar day period, through July 26, 2022, to comply with the US\$1.00 minimum bid price requirement for continued listing on the Nasdaq.

On July 15, 2022, we announced that our shareholders had approved consolidation of our issued and outstanding common shares on a twenty-five (25) to one (1) basis (the "Share Consolidation"), subject to approval of the Toronto Stock Exchange and the Nasdaq. On July 21, 2022 the Share Consolidation was effected and the Common Shares began trading on the TSX and Nasdaq on a post-Consolidation basis. The Share Consolidation reduced the number of Common Shares issued and outstanding from 121,397,007 to 4,855,876 Common Shares. Proportionate adjustments were made to the Company's outstanding warrants and stock options using the same ratio.

The Company proceeded with the Share Consolidation in order to satisfy the Bid Price Rule. As the Company did not trade at or above the US \$1.00 per Common Share for ten consecutive trading days by July 25, 2022, the current expiration date of its grace period, it received a notice of delisting on July 28, 2022. On August 3, 2022, Company received formal notice from Nasdaq that the Company evidenced compliance with the Bid Price Rule and all other applicable continued listing requirements and that the Nasdaq listing matter was closed.



Exposure to Epidemic or Pandemic Outbreak

Coronavirus, or COVID-19, a contagious disease that was characterized by the World Health Organization as a pandemic in early 2020, continues to affect the global community. The significant spread of COVID-19 resulted in a widespread health crisis and has had adverse effects on national economies generally, on the markets that we serve on our operations and on the market price of our common shares.

The spread of COVID-19 may continue to impact our operations, including the potential interruption of our clinical trial activities and of our supply chain. For example, the rise in the Omicron variant in the COVID-19 pandemic has caused delays in site initiation and patient enrollment in our Phase 3 DETECT clinical trial for diagnostic use in childhood-onset growth hormone deficiency. Additionally, sales activities for Macrilen™ in the U.S. may be impacted due to delays of diagnostic activities on AGHD in the U.S. Further, the COVID-19 pandemic may also cause some patients to be unwilling to enroll in our trials or be unable to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services, which would delay our ability to conduct clinical trials or release clinical trial results on a timely basis and could delay our ability to obtain regulatory approval and commercialize our product candidates. The spread of an infectious disease, including COVID-19, may also result in the inability of our suppliers to deliver components or raw materials on a timely basis or at all. In addition, hospitals may reduce staffing and reduce or postpone certain treatments in response to the spread of an infectious disease. Such events may result in a period of business disruption and, in reduced operations, doctors or medical providers may be unwilling to participate in our clinical trials, any of which could materially affect our business, financial condition or results of operations.

Given this rapidly evolving situation, the duration, scope and impact on our business operations, clinical studies and financial results have been and are expected to continue to be impacted by the pandemic, as discussed further below. Aeterna Zentaris has developed protocols and procedures should they be required to deal with any potential epidemics and pandemics and has implemented these protocols and procedures to address the current COVID-19 pandemic. Despite appropriate steps being taken to mitigate such risks, there can be no assurance that existing policies and procedures will ensure that the Company's operations will not be adversely affected. The COVID-19 pandemic has resulted in a widespread health crisis that has adversely affected the economies and financial markets of many regions and countries. There can be no assurance that a disruption in financial markets, regional economies and the world economy would not negatively affect Aeterna Zentaris' access to capital or its financial performance.

Uncertain factors, including the duration of the outbreak, the severity of the disease and the actions to contain or treat its impact, could impair our operations including, among other things, employee mobility and productivity, availability of our facilities, conduct of our clinical trials and the availability and the productivity of third-party product and service suppliers. Please see the risk factor section titled "The economic effects of a pandemic, epidemic or outbreak of an infectious disease could adversely affect our operations or the market price of our Common Shares" in our most recent Form 20-F.

Russia/Ukraine Conflict

Conducting clinical trials in foreign countries, as in our ongoing DETECT-trial, presents additional risks that may delay completion of our clinical trials. These risks include the failure of enrolled patients in foreign countries to adhere to clinical protocol as a result of differences in healthcare services or cultural customs, managing additional administrative burdens associated with foreign regulatory schemes, as well as political and economic risks, including war, relevant to such foreign countries. For example, we have engaged a CRO to conduct the DETECT-trial outside the United States, including in Russia and Ukraine, and clinical trial activities in those countries are being halted due to the war in Ukraine (which represents approximately 25 patients). To date, no patients have been enrolled in these clinical trials.

Furthermore, the United States and its European allies have imposed significant new sanctions against Russia, including regional embargoes, full blocking sanctions, and other restrictions targeting major Russian financial institutions. Our ability to conduct clinical trials in Russia, parts of Ukraine and elsewhere in the region have become restricted under applicable sanctions laws, which require us to identify alternative trial sites, thereby increasing our development costs and delaying the clinical development of our product candidates.



Condensed Interim Consolidated Statements of Comprehensive Income (Loss) Data
(in thousands, except share and per share data)

	Three months ended		Six months ended	
	June 30		June 30	
	2022	2021	2022	2021
		(As restated)	(As restated)	
	\$	\$	\$	\$
Revenues				
License fees	(206)	492	226	1,016
Development services	(77)	1,030	889	2,125
Product sales	—	—	57	0
Royalties	24	19	43	27
Supply chain	37	43	80	84
Total revenues	(222)	1,584	1,295	3,252
Operating expenses				
Cost of sales	13	12	92	41
Research and development expenses	2,398	1,768	4,788	3,226
General and administrative expenses	1,781	1,645	3,349	2,909
Selling expenses	302	318	605	564
Total operating expenses	4,494	3,743	8,824	6,740
Loss from operations	(4,716)	(2,159)	(7,529)	(3,488)
Gains (loss) due to changes in foreign currency exchange rates	502	82	676	(166)
Other finance costs	(2)	(7)	(3)	(17)
Net finance income (costs)	500	75	673	(183)
Loss before income taxes	(4,216)	(2,084)	(6,856)	(3,671)
Income tax recovery	—	—	—	129
Net loss	(4,216)	(2,084)	(6,856)	(3,542)
Other comprehensive income (loss):				
Items that may be reclassified subsequently to profit or loss:				
Foreign currency translation adjustments	42	(126)	79	421
Items that will not be reclassified to profit or loss:				
Actuarial gain (loss) on defined benefit plans	5,276	(968)	8,025	(86)
Comprehensive income (loss)	1,102	(3,178)	1,248	(3,207)
Net loss per share [basic and diluted]	(0.87)	(0.43)	(1.41)	(0.82)
Weighted average number of shares outstanding:				
Basic	4,855,876	4,848,129	4,855,876	4,335,821
Diluted	4,855,876	4,848,129	4,855,876	4,335,821

(1) This restatement is discussed below in the “Results of operations” section, subsection “Restatement of Comparative Period Figures”. The interim financial statements for the period ended June 30, 2021 have not been refiled, but the comparatives are corrected in the interim financial statements for the periods ended June 30, 2022 filed with this MD&A.



Condensed Interim Consolidated Statements of Financial Position Data

<i>(in thousands)</i>	As at June 30, 2022	As at December 31, 2021
	<u>\$</u>	<u>\$</u>
Cash and cash equivalents	58,157	65,300
Trade and other receivables and other current assets	4,755	5,447
Inventory	261	73
Restricted cash equivalents	314	335
Property, plant and equipment	42	42
Right of use assets	114	150
Other non-current assets	8,182	8,755
Total assets	71,825	80,102
Payables and accrued liabilities and income taxes payable	2,740	2,787
Current portion of provisions	27	34
Current portion of deferred revenues	3,534	4,815
Lease liabilities	122	161
Non-financial non-current liabilities ⁽¹⁾	11,108	19,319
Total liabilities	17,531	27,116
Shareholders' equity¹	54,294	52,986
Total liabilities and shareholders' equity	71,825	80,102

(1) Comprised mainly of employee future benefits, provisions and non-current portion of deferred revenues.

¹ Figures provided on a pre-Share Consolidation basis.



Critical Accounting Policies, Estimates and Judgments

The preparation of condensed interim consolidated financial statements in accordance with IFRS requires management to make judgments, estimates and assumptions that affect the reported amounts of the Company's assets, liabilities, revenues, expenses and related disclosures. Judgments, estimates and assumptions are based on historical experience, expectations, current trends and other factors that management believes to be relevant at the time at which the Company's condensed interim consolidated financial statements are prepared.

Management reviews, on a regular basis, the Company's accounting policies, assumptions, estimates and judgments in order to ensure that the consolidated financial statements are presented fairly and in accordance with IFRS applicable to interim financial statements. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.

Critical accounting estimates and assumptions, as well as critical judgments used in applying accounting policies in the preparation of the Company's condensed interim consolidated financial statements, were the same as those applied to the Company's annual consolidated financial statements for the year ended December 31, 2021.

The rise in COVID-19 variants has caused delays in site initiation and patient enrollment in our DETECT-trial and may be impacting sales activities for Macrilen™ in the U.S. Further, the continuation of the COVID-19 pandemic and the Russia/Ukraine has caused some patients to be unwilling to enroll in our trials or be unable to comply with clinical trial protocols if such events impede patient movement or interrupt healthcare services, both of which have delayed our ability to conduct clinical trials or release clinical trial results on a timely basis and delay our ability to obtain regulatory approval and commercialize our product candidates. For the six-month period ended June 30, 2022, management has assessed the impact of the uncertainties around the COVID-19 pandemic and the Russia/Ukraine conflict on our judgments, estimates, accounting policies and amounts recognized in our unaudited condensed interim consolidated financial statements. Management determined that the recruitment for the DETECT-trial is now likely to continue into 2023, as compared to the end of 2022 year, as anticipated at the end of 2021. Additional impacts are discussed below (see revenues under results of operations for the three-month period end June 30, 2022)

Financial Risk Factors and Other Financial Instruments

The nature and extent of our exposure to risks arising from financial instruments, including credit risk, liquidity risk and market risk and how we manage those risks are described in note 24 to the Company's audited consolidated financial statements for the year ended December 31, 2021. There were no significant changes in the three and six month periods of 2022 as compared to the December 31, 2021 disclosures.

Results of operations for the three and six-month periods ended June 30, 2022

Restatement of comparative period figures

In the fourth quarter of 2021, the Company restated its previously reported condensed consolidated interim financial statements for the three-month period ended March 31, 2021 and the three-month and six-month periods ended June 30, 2021 and three-month and nine-month periods ended September 30, 2021 with respect to the recognition of revenue for the Novo Amendment, signed in November 2020. During the fourth quarter of 2021, management reassessed the classification of the development activities associated with the DETECT-trial and concluded that subsequent to the Novo Amendment the parties no longer shared joint control of these activities and, as such, these development activities no longer met the definition of a joint operation, as defined in *IFRS 11, Joint Arrangements*. Therefore, pursuant to the guidance in *IFRS 15, Revenue from Contracts with Customers*, the Company reclassified the charges to Novo, from research and development expenses to development services revenue, in the related periods. In addition, the license fees related to the pediatric indication were adjusted to reflect the revised pattern of recognition as the performance obligation for the development services has now been combined with the pediatric license. In addition, the accounting for prepaid expenses and other assets and deferred revenues related the DETECT-trial expenses incurred was restated.



Below is the impact of the fourth quarter 2021 restatement on the June 30, 2021 financials (amounts in thousands, except for basic and diluted loss per share):

	<u>Previously reported</u>	<u>Effect of restatement</u>	<u>Amended</u>
	\$	\$	\$
Consolidated interim statement of loss and comprehensive loss for the three-month period ended June 30, 2021			
License fees	537	(45)	492
Development service revenues	—	1,030	1,030
Research and development expenses	738	1,030	1,768
Net loss	(2,039)	(45)	(2,084)
Total comprehensive loss	(3,133)	(45)	(3,178)
Basic and diluted loss per share	(0.42)	(0.01)	(0.43)
Consolidated interim statement of loss and comprehensive loss for the six-month period ended June 30, 2021			
License fees	1,074	(58)	1,016
Development service revenues	—	2,125	2,125
Research and development expenses	1,101	2,125	3,226
Net loss	(3,484)	(58)	(3,542)
Total comprehensive loss	(3,149)	(58)	(3,207)
Basic and diluted loss per share	(0.72)	(0.01)	(0.82)
Consolidated interim statement of financial position as of June 30, 2021			
Prepaid expenses and other current assets	3,308	1,067	4,375
Current portion of deferred revenues	2,125	1,111	3,236
Deficit	(326,229)	(58)	(326,287)

These restatements did not impact the Company's cash and cash equivalent amounts and reported amounts of operating, investing and financing activities within the consolidated interim statements of cash flows for the three and six-month periods ended June 30, 2021.

Results of operations for the three-month period ended June 30, 2022

For the three-month period ended June 30, 2022 we reported a consolidated net loss of \$4.2 million, or \$0.87 loss per common share (basic), as compared with a consolidated net loss of \$2.1 million, or \$0.43 loss per common share (basic) for the three-month period ended June 30, 2021. The \$2.1 million increase in net loss is primarily from \$1.8 million lower revenues, an increase in Operating expenses of \$0.7 million offset by a increase of \$0.4 million in Net Finance income.

Revenues

Our total revenue for the three-month period ended June 30, 2022 was (\$0.2) million as compared to \$1.6 million for the same period in 2021, representing a decrease of \$1.8 million.

Following joint discussions with Novo, management has determined that the overall costs associated with the DETECT-trial will increase substantially through the trial's expected completion date, which, as noted above, has been extended into 2023. Due to the increase in overall expected clinical trial costs, management has re-evaluate its estimate of the progress of the clinical trial and adjusted revenue accordingly.



As such, this resulted in reversal of revenue in both the license fees and development services for the quarter and in negative revenues of \$0.2 million and \$0.1 million for the three-months ended June 30, 2022.

Management's best estimates were utilized to calculate the additional costs and the impact it had on revenue with regards to the DETECT-trial. As such, our current estimates may change as we continue to monitor progress, which in turn may continue to be impacted both by COVID-19 and the Russia/Ukraine war, as well as by other factors currently unknown or inestimable, and/or finalize any necessary changes in scope or formalize other arrangements associated with the DETECT-trial. We will make necessary adjustments to the amounts and timing of revenues and deferred revenues as circumstances warrant. Potential adjustments in future periods may have additional impact on our consolidated financial statements.

During the first quarter of 2022, the Company shipped an initial batch of macimorelin (Ghryvelin®) to Consilient as they prepare to launch in the United Kingdom. There were no further shipments in the second quarter but this is set to resume in the third quarter in July 2022.

Operating expenses

Our total operating expenses for the three-month period ended June 30, 2022 was \$4.5 million as compared with \$3.7 million for the same period in 2021, representing an increase of \$0.8 million. This increase arose primarily from a \$0.6 million increase in research and development costs, \$0.2 million increase in general and administrative expenses, as further discussed below.

Research and development expenses

The following table summarizes our research and development expenses incurred during the periods indicated (amounts in thousands, except percentages):

	QUARTER ENDED				SIX MONTHS ENDED			
	JUNE 30,				JUNE 30,			
	2022	2021	\$	%	2022	2021	\$	%
	\$	\$	CHANGE	CHANGE	\$	\$	CHANGE	CHANGE
Macrilen™ (macimorelin) pediatric trial (DETECT-trial) direct research and development expenses	651	964	(313)	-32.5%	1,547	2,030	(483)	-23.8%
AEZS-130 direct research and development expenses	419	34	385	1132.0%	696	34	662	1947.0%
DC-PTH direct research and development expenses	447	48	399	831.3%	715	48	667	1389.6%
Parkinson's direct research and development expenses	161	—	161	100.0%	350	—	350	100.0%
Covid-19 direct research and development expenses	146	233	(87)	-37.3%	194	301	(107)	-35.5%
NMOSD direct research and development expenses	115	213	(98)	-46.0%	204	230	(26)	-11.3%
Chlamydia direct research and development expenses	107	—	107	100.0%	225	—	225	100.0%
Additional programs' direct research and development expenses	11	45	(34)	-75.6%	147	184	(37)	-20.1%
Total direct research and development expenses	2,057	1,537	520	33.8%	4,078	2,827	1,251	44.3%
Employee-related expenses	294	187	107	57.2%	618	323	295	91.3%
Facilities, depreciation, and other expenses	47	44	3	6.8%	92	76	16	21.1%
Total	2,398	1,768	630	35.6%	4,788	3,226	1,562	48.4%



Research and development expenses increased \$0.6 million for the quarter ended June 30, 2022 compared to the quarter ended June 30, 2021 primarily due to \$0.5 million increase in direct research and development expenses, which was primarily due to a \$0.8 million increase in the initiation of our new pre-clinical projects with universities offset by a \$0.3 million decrease in costs for the DETECT-trial. The Company had its six pre-clinical projects fully initiated in the quarter ended June 30, 2022 as compared to having started only two such projects in the same period in 2021.

Employee-related expenses have increased in 2022 by \$0.1 million for the quarter ended June 30, 2022 as compared to the quarter ended June 30, 2021 primarily from the impact of the addition of Dr. Michael Teifel as our Chief Scientific Officer in May 2021.

General and administrative expenses

General and administrative expenses increased by \$0.2 million for the quarter ended June 30, 2022 compared to the quarter ended June 30, 2021, primarily due to an increase in insurance costs of \$0.2 million. The increase in Insurance costs was due to additional policies that started in the third quarter of 2021 and which continue into 2022.

Net finance income

Our net finance income for the three-month period ended June 30, 2022 was \$0.5 million as compared with net finance income of \$0.1 million for the same period in 2021, representing an increase in net finance income of \$0.4 million. This is primarily due to a \$0.4 million increase in gain from favorable changes in foreign currency exchange rates on the US denominated cash held by the Company's German subsidiaries.

Results of operations for the six-month period ended June 30, 2022

For the six-month period ended June 30, 2022 we reported a consolidated net loss of \$6.9 million, or \$1.41 loss per common share (basic), as compared with a consolidated net loss of \$3.5 million, or \$0.82 loss per common share (basic) for the six-month period ended June 30, 2021. The \$3.4 million increase in net loss is primarily from \$2.0 million lower revenues, an increase in Operating expenses of \$2.1 million offset by a net \$0.7 million gain in Net Finance income and Income Tax recovery.

Revenues

Our total revenue for the six-month ended June 30, 2022 was \$1.3 million as compared to \$3.3 million for the same period in 2021, representing a decrease of \$2.0 million

The decrease in the six-month ended June 30, 2022 is driven by the reversal of revenue of \$0.4 million in license fees and \$0.8 million in development services which took place within the Q2 as discussed above (based on management's current best estimate related to additional cost associated to the DETECT-trial). The difference of \$0.8 million is attributed to reductions in our license fee and development services revenues, because of the delays and additional overall expected future costs associated with our DETECT-trial, as mentioned above.

During the first quarter of 2022, the Company shipped an initial batch of macimorelin (Ghryvelin®) to Consilient as they prepare to launch in the United Kingdom. There were no further shipments in the second quarter, but this is set to resume in the third quarter with launches in Germany and Finland in July 2022.



Operating expenses

Our total operating expenses for the six-month period ended June 30, 2022 was \$8.8 million as compared with \$6.7 million for the same period in 2021, representing an increase of \$2.1 million. This increase arose primarily from a \$1.6 million increase in research and development costs, \$0.4 million in general and administrative as a result of higher Insurance costs due to additional policies that started in the third quarter of 2021 and which continue into 2022. The balance of \$0.1 million relates to higher cost of sales and selling expenses.

Research and development expenses increased by \$1.6 million for the six-months ended June 30, 2022 compared to the six-months ended June 30, 2021 primarily due to \$1.7 million increase in direct research and development expenses, which was primarily due to an increase in the initiation of our new pre-clinical projects with universities, which saw an increase in activity in these projects in 2022. There was a \$0.4 million increase in employee plus facilities related expenses, offset by a \$0.5 million decrease in costs for the DETECT-trial caused by the delays that were previously mentioned (please refer to the table above Research and development expenses).

Selected quarterly financial data

<i>(in thousands, except for per share data)</i>	Three months ended			
	June 30,			Sep 30, 2021
	2022	Mar 31, 2022	Dec 31, 2021	(1)
	\$	\$	\$	\$
Revenues	(222)	1,517	956	1,052
Net loss	(4,216)	(2,640)	(2,894)	(1,932)
Net loss per share (basic and diluted) ⁽²⁾	(0.87)	(0.54)	(0.60)	(0.40)

<i>(in thousands, except for per share data)</i>	Three months ended			
	Jun 30, 2021	Mar 31,		Sep 30, 2020
	(1)	2021⁽¹⁾	Dec 31, 2020	
	\$	\$	\$	\$
Revenues	1,584	1,668	2,366	128
Net (loss) income	(2,084)	(1,458)	(1,311)	(1,136)
Net loss per share (basic and diluted) ⁽²⁾	(0.43)	(0.38)	(0.80)	(0.51)

(1) The restatements are also discussed above under “Revenues” in the Results from operations section of this MD&A. The interim financial statements for the periods ended March 31, 2021, June 30, 2021 and September 30, 2021 have not been refiled but the comparatives will be corrected when the interim financial statements for the periods ended March 31, 2022, June 30, 2022 and September 30, 2022 are filed. These restatements did not have any impact on 2020 results.

(2) Net loss per share is based on the weighted average number of shares outstanding during each reporting period, which may differ on a quarter-to-quarter basis. As such, the sum of the quarterly net loss per share amounts may not equal full-year net loss per share.

Historical quarterly results of operations and net loss cannot be taken as reflective of recurring revenue or expenditure patterns of predictable trends, largely given the non-recurring nature of certain components of our historical revenues, the impact of costs associated with launching a number of significant preclinical research and development programs in 2021, and of foreign exchange gains and losses. In addition, we cannot predict what the revenues from royalties will be earned from the Novo Amendment.



Use of cash and cash equivalents

We began the year 2022 with \$65.3 million in cash and cash equivalents. During the six-month period ended June 30, 2022, our operating activities consumed \$6.4 million, our financing activities and our investing activities used \$0.1 million and the impact of the foreign exchange fluctuations was \$0.7 million. As at June 30, 2022 we had \$58.2 million of cash and cash equivalents.

Liquidity and capital reserves

Our operations and capital expenditures have generally been financed through certain transactions impacting our cash flows from operating activities, public equity offerings, registered direct offerings and issuances. A portion of the Company's cash is held in AEZS Germany, which is the counterparty to various license, supply and distribution agreements for the Company's only approved product Macrilen™ (macimorelin).

Via public and private financings between September 2019 and February 2021, the Company has received \$55.9 million in total funding (net of transaction costs) and, throughout 2021, holders exercised 1.4 million warrants resulting in proceeds to the Company of \$20.1 million.

<i>(in thousands)</i>	<u>Three months ended June 30,</u>		<u>Six months ended June 30,</u>	
	<u>2022</u>	<u>2021</u>	<u>2022</u>	<u>2021</u>
Cash and cash equivalents - beginning of period	63,596	73,371	65,300	24,271
Cash used in operating activities	(4,850)	(3,635)	(6,311)	(4,680)
Cash flows (used in) provided by financing activities	(34)	24	(68)	50,957
Cash flows used in investing activities	(42)	(2)	(48)	(509)
Effect of exchange rate changes on cash and cash equivalents	(513)	110	(716)	(171)
Cash and cash equivalents - end of period	<u>58,157</u>	<u>69,868</u>	<u>58,157</u>	<u>69,868</u>

Operating Activities

Cash used by operating activities totaled \$4.9 million for the three-month and \$6.4 million in the six-month periods ended June 30, 2022, as compared to \$3.6 million and \$4.7 million in the same periods in 2021. This \$1.3 million increase in the three-months and \$1.7 million in the six-months ended June 30, 2022 in use of cash in operating activities is attributed primarily to increased research and development and general and administrative expenses.

Financing Activities

Cash used by financing activities totaled \$0.03 million for the three-months and consumed \$0.07 million in the six-month periods ended June 30, 2022, as compared with cash provided by financing activities of \$0.02 million and \$51 million in the same periods in 2021. On February 21, 2021, the Company completed the February 2021 financing with net cash proceeds of \$31.0 million and, throughout the first quarter of 2021, the warrant exercises contributed cash of approximately \$20.0 million.



Investing Activities

Cash used by investing activities totaled \$0.04 million for the three-months and \$0.05 million in the six-month periods ended June 30, 2022, as compared to cash used by investing activities of \$0.002 and \$0.5 million in the same periods in 2021. During the first six months of 2021, the Company executed various agreements including in-licensing and similar arrangements with development partners reflecting the purchase of separately acquired intangible assets of \$0.5 million.

Capital stock

On July 21, 2022, the Share Consolidation was effected and the Common Shares began trading on the TSX and Nasdaq on a post-Consolidation basis. The Share Consolidation reduced the number of Common Shares issued and outstanding from 121,397,007 Common Shares to 4,855,876 Common Shares. Proportionate adjustments were made to the Company's outstanding warrants and stock options. The Share Consolidation has been retrospectively reflected in our June 30, 2022 results, as 4,855,876 common shares issued and outstanding, as well as 43,455 stock options, 16,920 deferred share units and 457,649 warrants outstanding.² Each stock option, deferred share unit and warrant is exercisable for one common share.

Adequacy of financial resources

Since inception, the Company has incurred significant expenses in its efforts to develop and co-promote products. Our current business focus is to: investigate further therapeutic uses of Macrilen™, expand pipeline development activities, further expand the commercialization of macimorelin in available territories and fund our 50% share of the DETECT-trial costs which exceed €9 million. Consequently, the Company has incurred operating losses and has generated negative cash flow from operations historically and in each of the last several years except for the year ended December 31, 2018 when the Company earned revenue from the sale of a license for the adult indication of Macrilen™ (macimorelin) in the U.S. and Canada. The Company expects to incur significant expenses and operating losses for the foreseeable future as it advances its product candidates through preclinical and clinical development, seeks regulatory approval and pursues commercialization of any approved product candidates. We expect that our research and development costs will increase in connection with our planned research and development activities.

As of June 30, 2022, the Company had cash and cash equivalents of \$58.2 million and an accumulated deficit of \$333.4 million. The Company also had a net loss of \$4.2 million and negative cash flows from operations of \$5.4 million for the three-months ended June 30, 2022. We believe that our existing cash on hand will be sufficient to fund our anticipated operating and capital expenditure requirements through 2023. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our capital resources sooner than we expect. We may also require additional capital to pursue in-licenses or acquisitions of other product candidates.

Contractual obligations and commitments as at June 30, 2022

<i>(in thousands)</i>	<u>Service and manufacturing</u>	<u>R&D contracts</u>	<u>TOTAL</u>
	\$	\$	\$
Less than 1 year	5,015	2,090	7,105
1 - 3 years	938	776	1,714
4 - 5 years	47	—	47
More than 5 years	—	—	—
Total	6,000	2,866	8,866

² On July 21, 2022, the Share Consolidation was effected and the Common Shares began trading on the TSX and Nasdaq on a post-Consolidation basis. The Share Consolidation reduced the number of Common Shares issued and outstanding from 121,397,007 Common Shares to 4,855,876 Common Shares. Proportionate adjustments were made to the Company's outstanding warrants and stock options.



During 2021, the Company executed various agreements including in-licensing and similar arrangements with development partners with \$0.6 million in additions of separately acquired intangible assets recognized in the condensed interim consolidated statements of financial position. Such agreements may require the Company to make payments on achievement of stages of development, launch or revenue milestones, although the Company generally has the right to terminate these agreements at no penalty. The Company recognizes research and development milestones as an intangible asset once it is committed to the payment, which is generally when the Company reaches a set point in the development cycle.

Based on the closing exchange rates at June 30, 2022, the Company expects to pay \$9,050 including \$6,804 (€6.5 million), and \$1,396 (£1.2 million) and \$850 USD, in R&D milestone payments and up to \$39,302, including \$28,785 (€27.6 million); \$1,517 (£1.3 million) and \$9,000 USD, in revenue related milestone payments. The table below contains all potential R&D and revenue-related milestone payments that the Company may be required to make under such agreements:

<i>(in thousands)</i>	Future potential R&D milestone payments	Future potential revenue milestone payments	TOTAL
	\$	\$	\$
Less than 1 year	26	—	26
1 - 3 years	204	—	204
4 - 5 years	1,990	—	1,990
More than 5 years	6,830	39,302	46,132
Total	9,050	39,302	48,352

The future payments that are disclosed represent contract payments and are not discounted and are not risk-adjusted. The development of any pharmaceutical product candidates is a complex and risky process that may fail at any stage in the development process due to a number of factors. The timing of the payments is based on the Company's current best estimate of achievement of the relevant milestone.

Contingencies

In the normal course of operations, the Company may become involved in various claims and legal proceedings related to, for example, contract terminations and employee-related and other matters.

Related Party Transactions and Off-Balance Sheet Arrangements

Other than employment agreements and indemnification agreements with our management, there are no related party transactions.

As at June 30, 2022, we did not have any interests in special purpose entities or any other off-balance sheet arrangements.

Risk Factors and Uncertainties

An investment in our securities involves a high degree of risk. In addition to the other information included in this MD&A and in the related consolidated financial statements, investors are urged to carefully consider the risks described under the caption "Risk Factors" in our most recent Annual Report on Form 20-F for the year ended December 31, 2021 for a discussion of the various risks that may materially affect our business. The risks and uncertainties not presently known to us or that we currently deem immaterial may also materially harm our business, operating results and financial condition and could result in a complete loss of your investment.



Our most recent Annual Report on Form 20-F was filed with the relevant Canadian and U.S. securities' regulatory authorities at www.sedar.com and with the SEC at www.sec.gov. Investors are urged to consult the risk factors in these documents.

Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including the Chief Executive Officer and the Chief Financial Officer, we have evaluated the effectiveness of our disclosure controls and procedures as at June 30, 2022. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that these disclosure controls and procedures were not effective as of that date due to a material weakness in internal control over financial reporting disclosed in our Annual Report on Form 20-F for the year ended December 31, 2021 available on SEDAR at www.sedar.com and on EDGAR at sec.gov and as described below.

Management's Report on Internal Control over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with IFRS as issued by the IASB.

Our internal control over financial reporting includes those policies and procedures that: (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of Aeterna Zentaris; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with IFRS, and that receipts and expenditures of the Company are being made only in accordance with authorizations of Company management; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of Company assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Material weakness

The material weakness that we identified in our internal controls over financial reporting as of December 31, 2021 was as follows: our review control was not sufficiently designed to adequately review and assess an accounting analysis for revenue recognition for complex revenue arrangements. This resulted in a restatement of our previously issued condensed interim consolidated financial statements as at and for the quarters and year-to-date periods ended March 31, 2021, June 30, 2021 and September 30, 2021, with respect to revenue recognition on one agreement.

We have developed and commenced implementation of a remediation plan to address the material weakness discussed above and to improve our internal control over financial reporting. The remediation plan includes:

- strengthening our revenue recognition and financial reporting controls by adding new or additional resources with adequate technical knowledge and training, including the hiring of a new Chief Financial Officer in January 2022, and utilizing the services of an external professional with requisite knowledge and experience in the area of revenue recognition and of IFRS more broadly.
- designing and implementing effective internal controls related to the involvement of appropriate finance and accounting staff in the review of strategic and complex transactions, such as license and collaboration agreements, including as those transactions are negotiated and executed, to ensure that any matters with accounting ramifications are addressed on a timely basis; and
- ensuring that all non-routine transactions, including those requiring the application of significant judgment or analysis, are thoroughly researched at the appropriate level and are sufficiently documented by qualified accounting and finance personnel (including third-party subject matter experts as necessary), with such documentation to be approved in a timely manner by the Company's Chief Financial Officer.

This material weakness will continue to be addressed through 2022.

Changes in Internal Controls over Financial Reporting

There have been no significant changes to our internal controls over financial reporting for the three and six-month period ended June 30, 2022 that have materially affected, or are reasonably likely to materially affect, internal controls over financial reporting.

**FORM 52-109F2
CERTIFICATION OF INTERIM FILINGS
FULL CERTIFICATE**

I, Klaus Paulini, **Chief Executive Officer, Aeterna Zentaris Inc.**, certify the following:

1. **Review:** I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Aeterna Zentaris Inc. (the “issuer”) for the interim period ended June 30, 2022.
2. **No misrepresentations:** Based on my knowledge, having exercised reasonable diligence, the interim filings do not contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, with respect to the period covered by the interim filings.
3. **Fair presentation:** Based on my knowledge, having exercised reasonable diligence, the interim financial report together with the other financial information included in the interim filings fairly present in all material respects the financial condition, financial performance and cash flows of the issuer, as of the date of and for the periods presented in the interim filings.
4. **Responsibility:** The issuer’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (DC&P) and internal control over financial reporting (ICFR), as those terms are defined in National Instrument 52-109 *Certification of Disclosure in Issuers’ Annual and Interim Filings*, for the issuer.
5. **Design:** Subject to the limitations, if any, described in paragraphs 5.2 and 5.3, the issuer’s other certifying officer(s) and I have, as at the end of the period covered by the interim filings
 - (a) designed DC&P, or caused it to be designed under our supervision, to provide reasonable assurance that
 - (i) material information relating to the issuer is made known to us by others, particularly during the period in which the interim filings are being prepared; and
 - (ii) information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation; and
 - (b) designed ICFR, or caused it to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuer’s GAAP.
- 5.1 **Control framework:** The control framework the issuer’s other certifying officer(s) and I used to design the issuer’s ICFR is Internal Control – Integrated Framework: 2013, issued by the Committee of Sponsoring Organizations of the Treadway Commission.
- 5.2 **ICFR – material weakness relating to design:** The issuer has disclosed in its interim MD&A for each material weakness relating to design existing at the end of the interim period
 - 1 a description of the material weakness;
 - 2 the impact of the material weakness on the issuer’s financial reporting and its ICFR; and
 - 3 the issuer’s current plans, if any, or any actions already undertaken, for remediating the material weakness.

5.3 N/A

6. **Reporting changes in ICFR:** The issuer has disclosed in its interim MD&A any change in the issuer's ICFR that occurred during the period beginning on January 1, 2022 and ended on March 31, 2022 that has materially affected, or is reasonably likely to materially affect, the issuer's ICFR.

Date: August 3, 2022

/s/ Klaus Paulini

Klaus Paulini
Chief Executive Officer

**FORM 52-109F2
CERTIFICATION OF INTERIM FILINGS
FULL CERTIFICATE**

I, Giuliano La Fratta, **Chief Financial Officer, Aeterna Zentaris Inc.**, certify the following:

1. **Review:** I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Aeterna Zentaris Inc. (the “issuer”) for the interim period ended June 30, 2022.
2. **No misrepresentations:** Based on my knowledge, having exercised reasonable diligence, the interim filings do not contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, with respect to the period covered by the interim filings.
3. **Fair presentation:** Based on my knowledge, having exercised reasonable diligence, the interim financial report together with the other financial information included in the interim filings fairly present in all material respects the financial condition, financial performance and cash flows of the issuer, as of the date of and for the periods presented in the interim filings.
4. **Responsibility:** The issuer’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (DC&P) and internal control over financial reporting (ICFR), as those terms are defined in National Instrument 52-109 *Certification of Disclosure in Issuers’ Annual and Interim Filings*, for the issuer.
5. **Design:** Subject to the limitations, if any, described in paragraphs 5.2 and 5.3, the issuer’s other certifying officer(s) and I have, as at the end of the period covered by the interim filings
 - (a) designed DC&P, or caused it to be designed under our supervision, to provide reasonable assurance that
 - (i) material information relating to the issuer is made known to us by others, particularly during the period in which the interim filings are being prepared; and
 - (ii) information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation; and
 - (b) designed ICFR, or caused it to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuer’s GAAP.
- 5.1 **Control framework:** The control framework the issuer’s other certifying officer(s) and I used to design the issuer’s ICFR is Internal Control – Integrated Framework: 2013, issued by the Committee of Sponsoring Organizations of the Treadway Commission.
- 5.2 **ICFR – material weakness relating to design:** The issuer has disclosed in its interim MD&A for each material weakness relating to design existing at the end of the interim period
 - 1 a description of the material weakness;
 - 2 the impact of the material weakness on the issuer’s financial reporting and its ICFR; and
 - 3 the issuer’s current plans, if any, or any actions already undertaken, for remediating the material weakness.

5.3 N/A

6. **Reporting changes in ICFR:** The issuer has disclosed in its interim MD&A any change in the issuer's ICFR that occurred during the period beginning on January 1, 2022 and ended on March 31, 2022 that has materially affected, or is reasonably likely to materially affect, the issuer's ICFR.

Date: August 3, 2022

/s/ Giuliano La Fratta

Giuliano La Fratta
Chief Financial Officer